211 related articles for article (PubMed ID: 30072096)
41. The Identification of Potential Therapeutic Targets for Cutaneous Squamous Cell Carcinoma.
McHugh A; Fernandes K; Chinner N; Ibrahim AFM; Garg AK; Boag G; Hepburn LA; Proby CM; Leigh IM; Saville MK
J Invest Dermatol; 2020 Jun; 140(6):1154-1165.e5. PubMed ID: 31705877
[TBL] [Abstract][Full Text] [Related]
42. Artesunate restrains the malignant progression of human cutaneous squamous cell carcinoma cells via the suppression of the PI3K/AKT pathway.
Huang X; Zhang S; Wang W
Tissue Cell; 2022 Jun; 76():101789. PubMed ID: 35338984
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
44. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
[TBL] [Abstract][Full Text] [Related]
45. Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization.
DeTemple VK; Walter A; Bredemeier S; Gutzmer R; Schaper-Gerhardt K
Arch Dermatol Res; 2024 Jun; 316(7):341. PubMed ID: 38847867
[TBL] [Abstract][Full Text] [Related]
46. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
47. Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma.
Claerhout S; Verschooten L; Van Kelst S; De Vos R; Proby C; Agostinis P; Garmyn M
Int J Cancer; 2010 Dec; 127(12):2790-803. PubMed ID: 21351258
[TBL] [Abstract][Full Text] [Related]
48. Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines.
Chen W; Leiter A; Yin D; Meiring M; Louw VJ; Koeffler HP
Int J Oncol; 2010 Sep; 37(3):737-43. PubMed ID: 20664943
[TBL] [Abstract][Full Text] [Related]
49. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
50. C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells.
Nissinen L; Riihilä P; Viiklepp K; Rajagopal V; Storek MJ; Kähäri VM
Sci Rep; 2024 Jun; 14(1):13465. PubMed ID: 38866870
[TBL] [Abstract][Full Text] [Related]
51. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
52. Downregulation of estrogen-related receptor alpha inhibits human cutaneous squamous cell carcinoma cell proliferation and migration by regulating EMT via fibronectin and STAT3 signaling pathways.
Chen H; Pan J; Zhang L; Chen L; Qi H; Zhong M; Shi X; Du J; Li Q
Eur J Pharmacol; 2018 Apr; 825():133-142. PubMed ID: 29476880
[TBL] [Abstract][Full Text] [Related]
53. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
54. Anticancer effects of cantharidin in A431 human skin cancer (Epidermoid carcinoma) cells in vitro and in vivo.
Li CC; Yu FS; Fan MJ; Chen YY; Lien JC; Chou YC; Lu HF; Tang NY; Peng SF; Huang WW; Chung JG
Environ Toxicol; 2017 Mar; 32(3):723-738. PubMed ID: 27113412
[TBL] [Abstract][Full Text] [Related]
55. GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells.
Tang JY; Dai T; Zhang H; Xiong WJ; Xu MZ; Wang XJ; Tang QH; Chen B; Xu M
Biochem Biophys Res Commun; 2014 Oct; 453(3):533-8. PubMed ID: 25285629
[TBL] [Abstract][Full Text] [Related]
56. Echinatin suppresses cutaneous squamous cell carcinoma by targeting GSTM3-mediated ferroptosis.
Kang Z; Wang P; Wang B; Yan Y; Zhao Z; Li C; Wen L; Wu M; Yan G; Wang X; Zhang G; Zeng Q
Phytomedicine; 2024 Aug; 131():155752. PubMed ID: 38833947
[TBL] [Abstract][Full Text] [Related]
57. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
58. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
59. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.
Liu Y; Chen S; Xue R; Zhao J; Di M
Biochem Biophys Res Commun; 2016 Feb; 470(2):350-355. PubMed ID: 26780727
[TBL] [Abstract][Full Text] [Related]
60. Increasing the therapeutic efficacy of docetaxel for cutaneous squamous cell carcinoma through the combined inhibition of phosphatidylinositol 3-kinase/AKT signalling and autophagy.
Wright TJ; McKee C; Birch-Machin MA; Ellis R; Armstrong JL; Lovat PE
Clin Exp Dermatol; 2013 Jun; 38(4):421-3. PubMed ID: 23530461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
